These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 16086620

  • 1. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
    Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M.
    J Clin Psychiatry; 2005 Aug; 66(8):1038-42. PubMed ID: 16086620
    [Abstract] [Full Text] [Related]

  • 2. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
    Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA.
    J Clin Psychiatry; 2005 Oct; 66(10):1326-30. PubMed ID: 16259548
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    Fava M, Thase ME, DeBattista C.
    J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
    [Abstract] [Full Text] [Related]

  • 4. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
    Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M.
    J Clin Psychiatry; 2004 Feb; 65(2):217-21. PubMed ID: 15003076
    [Abstract] [Full Text] [Related]

  • 5. T3 augmentation of SSRI resistant depression.
    Abraham G, Milev R, Stuart Lawson J.
    J Affect Disord; 2006 Apr; 91(2-3):211-5. PubMed ID: 16483669
    [Abstract] [Full Text] [Related]

  • 6. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
    Ninan PT, Hassman HA, Glass SJ, McManus FC.
    J Clin Psychiatry; 2004 Mar; 65(3):414-20. PubMed ID: 15096082
    [Abstract] [Full Text] [Related]

  • 7. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression.
    Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M.
    Ann Clin Psychiatry; 2002 Mar; 14(1):33-8. PubMed ID: 12046638
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
    Kaplan EM.
    Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
    [Abstract] [Full Text] [Related]

  • 10. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
    Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B.
    Arch Gen Psychiatry; 2007 Jun; 64(6):679-88. PubMed ID: 17548749
    [Abstract] [Full Text] [Related]

  • 11. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Lesser IM, Kornstein SG, Wisniewski SR, Rush AJ, Shelton RC.
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [Abstract] [Full Text] [Related]

  • 12. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
    Perry EB, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS.
    J Clin Psychiatry; 2004 Feb; 65(2):238-43. PubMed ID: 15003079
    [Abstract] [Full Text] [Related]

  • 13. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R, Chen J, Entsuah AR, Schatzberg AF.
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [Abstract] [Full Text] [Related]

  • 14. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors.
    Konuk N, Atasoy N, Atik L, Akay O.
    Adv Ther; 2006 Mar; 23(4):646-54. PubMed ID: 17050507
    [Abstract] [Full Text] [Related]

  • 15. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
    Karp JF, Whyte EM, Lenze EJ, Dew MA, Begley A, Miller MD, Reynolds CF.
    J Clin Psychiatry; 2008 Mar; 69(3):457-63. PubMed ID: 18251622
    [Abstract] [Full Text] [Related]

  • 16. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM, Dellva MA, Waterman K, Greenbaum M, Poppe C, Goldberger C, Ahl J, Perahia DG.
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [Abstract] [Full Text] [Related]

  • 17. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ, Jiang Q.
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [Abstract] [Full Text] [Related]

  • 18. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR, Huang H, Thase ME.
    J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
    [Abstract] [Full Text] [Related]

  • 19. Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder.
    Agid O, Shalev AY, Lerer B.
    J Clin Psychiatry; 2001 Mar; 62(3):169-73. PubMed ID: 11305702
    [Abstract] [Full Text] [Related]

  • 20. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
    Mowla A, Kardeh E.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):970-3. PubMed ID: 21291943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.